Mixing Stemoxydine 5% with premixed solution of RU58841 5% 4/15/2024
The user is using Dutasteride, Nizoral, and RU58841 for hair loss and is considering mixing RU58841 with Stemoxydine for better scalp coverage but is concerned about the potential degradation of RU58841 when mixed with a water-based solution. They are seeking advice on the feasibility of this mixture.
View this post in the Community ā
Similar Community Posts Join
5 / 5 resultscommunity RU58841 User Feedback - How many of you has it helped
RU58841 has helped many users reduce hair shedding and improve hair thickness, with some experiencing side effects like libido changes. Users often combine it with other treatments like minoxidil, finasteride, and ketoconazole shampoo for better results.
community Influencers and their recommendations
Bryan Johnson uses Dutasteride, Latanoprost, Minoxidil with Tretinoin, and other unproven treatments, while Derek uses Finasteride, Minoxidil, Nizoral, RU58841, and Castor Oil. Kevin uses Finasteride, Minoxidil, RU58841, and Alfatradiol, but is against Nizoral and microneedling, preferring Tretinoin for absorption.
community Iām on a crazy hairloss stack and Iām still losing hair and not experiencing any regrowth. What is going on?
The user is using a combination of hair loss treatments including finasteride, stemoxydine, oral minoxidil, RU58841, dermastamping, ketoconazole shampoo, collagen, Viviscal, and biotin, and has improved their diet. Despite these efforts, they are still experiencing hair shedding and scalp itchiness, and are considering increasing their minoxidil dosage or starting dutasteride.
community Just wanted to provide a little reassurance
A user shared their positive experience with a hair loss treatment regimen including Dutasteride, Minoxidil, RU58841, Nizoral, microneedling, and supplements, reporting no side effects and some hair regrowth. They encouraged others not to fear these treatments, as they are generally safe.
community DIY Testosterone replacement therapy and fin
An 18-year-old is considering testosterone replacement therapy with finasteride or dutasteride for hair loss but worries about side effects. Users recommend alternatives like minoxidil, RU58841, and consulting a doctor.
Related Research
6 / 6 resultsresearch Antiandrogens and Androgen Inhibitors
This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Experimental and early investigational drugs for androgenetic alopecia
This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.
research Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA
This pilot study found that a novel regimen including NuH Hair led to significant hair growth in male patients with androgenic alopecia, regardless of atopy status, with quicker results when additional treatment components were used.
research Faculty Opinions recommendation of Promising therapies for treating and/or preventing androgenic alopecia.
There are several promising treatments for hair loss, including dutasteride, latanoprost, ketoconazole shampoo, anti-androgens, laser/light treatment, and platelet-rich plasma, but more research is needed.
research Female pattern hair loss
Female pattern hair loss, common in women, can be treated with various methods like minoxidil, anti-androgen treatments, and light therapy, but early intervention and realistic expectations are crucial.
research Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review
This study reported that while no effective treatment exists for frontal fibrosing alopecia, oral 5-alpha-reductase inhibitors showed the most promise, inducing a good clinical response in 45% of patients.